Starting from Jan. 20, each consumer can receive a maximum subsidy of 500 yuan per item, with a limit of one subsidized item per category, per the plan. Equal support should be given to both domestic ...

ZTE has emerged as the leading ... transitioning from a backup broadband technology in previous cellular generations to a viable alternative for both consumer and enterprise verticals due to ...

Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...

Instead, the phone relays the text messages using orbiting Starlink satellites, giving consumers a way to remain connected in cellular dead zones, similar to Apple’s Emergency SOS satellite ...

That's right, a phone network (of sorts) on the Moon! The network is called Lunar Surface Communication System (LSCS), and it is basically a replica of the 4G/LTE cellular technology currently ...

Consumer spending will play a large role in the economy in 2025, as it always does. However, the impact has often been overstated. Nonetheless, the strong footing of households—in the aggregate ...

FWA of previous cellular generations was viewed as a backup or placeholder broadband technology for both the consumer and enterprise ... and security features. ZTE led the competitive ranking ...

It looks like T-Mobile is now accepting customers into the free beta program for SpaceX’s cellular Starlink service—but only if you have the latest Samsung handsets. On Tuesday, a number of T ...

8, 2024. (AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for ... after the company spun off its consumer health unit in 2023.